TuberculosisCaPThaiNCT05581212
TB Case-Finding, Treatment and Prevention Intervention in Thailand
A study testing Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack in people with Tuberculosis, run by Institut de Recherche pour le Developpement at 20 sites in Thailand.
Trial summary
The project aimed to test a strategy for the early detection and prevention of tuberculosis in household contacts of tuberculosis patients in order to reduce the morbidity, mortality and transmission of this disease in Thailand. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Tuberculosis
- What is being tested?
- Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 7,455 participants
- Where
- 20 sitesThailand
- Study dates
- 7 May 2024to 7 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Age ≥18 years
- Newly bacteriologically confirmed TB case (within 1 month of diagnosis)
- Living in the same household for the last 3 months
- Reporting at least one HH contact
- Providing written informed consent for participation in the study
- All contacts living in the same HH, defined as any person who shared the same enclosed living space as the index TB case for one or more nights or for frequent or extended daytime periods for at least one month before the TB diagnosis is made.
- Providing written informed consent (signed by adult (≥18 years) contacts; or by parents/guardians for minors < 13 years or incapacitated people; written assent for children ≥13 years and < 18 years).
Who cannot join
- Index case who do not live in the catchment area of the study cluster
- Index cases diagnosed with rifampicin resistance, multidrug resistance (MDR) or extensively drug-resistant (XDR-TB)
- Index cases who are incarcerated
- contact currently on TPT or on TB treatment or who finished such treatment in the last 3 months.
Trial locations and contacts
20 sites in 1 country.
20 sites in 1 country
Thailand20 sites
Bang Lamung H.
Bang Lamung
Nakornping H.
Chiang Mai
Chiangrai Prachanukroh H.
Chiang Rai
Chon Buri H.
Chon Buri
Kalasin H.
Kalasin
Khon Kaen H.
Khon Kaen
Lampang H.
Lampang
Samut Prakan H.
Mueang Samut Prakan
Buriram H.
Nakhon Ratchasima
Surin H.
Nakhon Ratchasima
Maharaj Nakhon Si Thammarat H.
Nakhon Si Thammarat
Phra Nakhon Si Ayutthaya H.
Phra Nakhon Si Ayutthaya
Ratchaburi H.
Ratchaburi
Samut Sakhon H.
Samut Sakhon
Si Sa Ket H.
Si Sa Ket
Hat Yai H.
Songkhla
Songkhla H.
Songkhla
Surat Thani H.
Surat Thani
Trang H.
Trang
Sunpasitthiprasong H.
Ubon Ratchathani
About this study
Official title: Implementation of a New Strategic TB Case-Finding, Treatment and Prevention Public Health Pack in Thailand
The project aimed to test a strategy for the early detection and prevention of tuberculosis in household contacts of tuberculosis patients in order to reduce the morbidity, mortality and transmission of this disease in Thailand. This strategy will be evaluated in comparison with the current programmatic approach through a pragmatic trial with cluster randomization (cluster randomized controlled trial) which will be conducted over the next 3 years. This project is carried out in collaboration with the Tuberculosis Division of the Ministry of Public Health of Thailand, the TB/HIV Research Foundation in Thailand and the London School of Hygiene and Tropical Medicine in England.
Read the detailed description
Title: Implementation of a new Strategic TB Case-Finding, Treatment and Prevention Public Health Pack in Thailand (CapThai) Phase: IV, cluster randomized trial
Population:
adults (>= 18 years old) with pulmonary TB and their household contacts. Sites: 20 clusters (provincial hospitals) in Thailand
Duration of the study:
36 months
Subject participation duration:
9 months
Description of the intervention:
Combined active case-finding, treatment and prevention of TB amongst household contacts of TB cases, associated with initiation of SOC treatment in active TB cases and initiation of TB preventive therapy in those contacts without active TB, based on free screening. This intervention will be compared to the standard of care available in the country.
Overall objective:
To evaluate whether a public health intervention package focusing on the households of newly detected TB cases can increase active case-finding and uptake of TB preventive therapy in Thailand.
Specific objectives:
- to compare the initiation and completion of TPT regimens amongst household contacts of infectious TB patients, overall and by gender and age group;
- to evaluate the safety of short TPT regimens amongst HH contacts, overall and by gender and age group;
- to compare the detection of TB and treatment uptake for active TB amongst HH contacts of infectious TB patients, overall and by gender and age group;
- to assess the feasibility of the combined intervention among health care providers and beneficiaries, by gender and age group;
- to assess the acceptability of the combined intervention among health care providers and beneficiaries, by gender and age group;
- to evaluate the epidemiological impact of the combined intervention.
Study design:
The study uses a Stepped-Wedge Cluster Randomised Trial design. Randomisation will take place at the hospital level (cluster: provincial hospitals with >150 new TB cases/year). Twenty clusters will be enrolled and switch from the control to the intervention phase in four sequences every 3 months in a random order until all clusters are exposed to the intervention.
- Intervention Phase: Newly detected bacteriologically confirmed TB patients (≥ 18 years) will be sensitized on the importance of HH contact investigation and TB stigma reduction. They will be asked to enumerate all contacts (name/age/sex/relationship) living in their HH for>1 month at the date of TB diagnostic. Screening invitation cards will be provided for each HH contact (or caregiver for children <13 years old), inviting them to attend the TB clinic at the selected hospital for free screening and evaluation. Transportation fees will be provided. Contacts detected with active TB will receive recommended treatment. In contacts for whom active TB is formally excluded, TPT will be initiated with the new short regimens: (i) children <2 years: isonicotine hydrazine (INH)+rifampicin daily for 3 months; (ii) children 2-12 years: INH+rifapentine weekly for 3 months; (iii) children≥13 and adults: INH+rifapentine daily for 1 month.
- Control phase: current strategy relying on passive case detection and advice provided to TB patients to refer HH contacts to the TB clinic for screening. The index TB patient will be asked to enumerate HH contacts as above and inform them on the need to be screened at the TB clinic.
Endpoints:
Primary endpoint: Proportion of HH contacts with active TB excluded who are initiated on TPT within 4 weeks of the index TB patient diagnosis - overall, by age group (<15, ≥15 years) and gender.
Secondary endpoints:
- Proportion of participants initiated on TPT who completed TPT;
- Proportion of participants in the Intervention phase who were initiated on TPT for whom treatment is discontinued due to intolerance, adverse events, or severe adverse events;
- Proportion of HH contacts with newly diagnosed active TB initiated on curative treatment within 8 weeks of the index TB case diagnosis - overall, by age group (<15, ≥15 years) and gender;
- Proportion of household contacts diagnosed with TB who completed TB treatment in the intervention vs. control phase;
- Proportion of contacts receiving TPT who developed TB over the 9 months follow-up period in the intervention vs. control phase.
Estimated time to complete enrollment:
12-15 months
- Conditions
- Tuberculosis
- Being tested
- Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack
- Keywords
- Case-finding, Preventive treatment, Public Health Pack, Household contacts
- Medical subject headings
- Tuberculosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tuberculosis Case-Finding, Treatment and Prevention Public Health PackOther
Combined active case-finding, treatment and prevention of TB amongst HH contacts of TB cases, associated with initiation of standard of care (SOC) treatment in active TB cases and initiation of TB preventive therapy in those contacts without active TB, based on free screening. This intervention will be compared to the standard of care available in the country.
| Study group | Role | What they receive |
|---|---|---|
| Standard of Care (Control phase) | No intervention | In the current standard of care in Thailand, at time of diagnosis and tuberculosis (TB) treatment initiation, TB patients are being advised to tell their household (HH) contacts to consult at the TB clinic for screening and provision of either curative or preventive treatment - according to the screening outcome. |
| Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack (Intervention phase) | Experimental | In the selected provinces, individuals (≥18 years) with newly detected bacteriologically confirmed pulmonary Tuberculosis (index TB case) will be sensitized on the importance of HH contact investigation for detection and prevention of TB and stigma reduction.
Index TB cases will be asked to enumerate all persons living in their HH for ≥1 month at the date of TB diagnostic (contact list), and provide their name/age/sex and relationship with the index case.
Screening will be offered to each HH contact, using screening invitation cards that will be provided to the index TB case, to be handed over to each HH contact (or caregiver for children <13 years old).
Urban and Village Health Volunteers (U/VHV),will visit the HH to enhance awareness of the importance of screening for TB case-finding and prevention and facilitate liaison with the hospital.
If active tuberculosis has been formally excluded, they will be eligible to receive the Tuberculosis Preventive Treatment (TPT). Receives: Other: Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - overall
Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - overall
Measured: Month18
Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - by age group (<15, ≥15 years)
Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - by age group (<15, ≥15 years)
Measured: Month18
Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - by gender
Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - by gender
Measured: Month18
Secondary outcomes (5)
Proportion of participants initiated on TPT who completed TPT
Proportion of participants initiated on TPT who completed TPT
Measured: Month 18
Proportion of participants who initiate TPT for whom treatment is discontinued due to adverse events or intolerance in the Intervention phase
Proportion of participants who initiate TPT for whom treatment is discontinued due to adverse events or intolerance in the Intervention phase
Measured: Month 18
Proportion of HH contacts with newly diagnosed active TB initiated on curative treatment within 4 weeks of the index TB patient diagnosis - overall
Proportion of HH contacts with newly diagnosed active TB initiated on curative treatment within 4 weeks of the index TB patient diagnosis - overall
Measured: Month 18
Proportion of HH contacts with newly diagnosed active TB initiated on curative treatment within 4 weeks of the index TB patient diagnosis - by age group (<15, ≥15 years)
Proportion of HH contacts with newly diagnosed active TB initiated on curative treatment within 4 weeks of the index TB patient diagnosis - by age group (<15, ≥15 years)
Measured: Month 18
Proportion of HH contacts with newly diagnosed active TB initiated on curative treatment within 4 weeks of the index TB patient diagnosis - by gender
Proportion of HH contacts with newly diagnosed active TB initiated on curative treatment within 4 weeks of the index TB patient diagnosis - by gender
Measured: Month 18
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Oct 2022
- Study start7 May 2024
- Primary completion6 Jan 2026
- Study completion7 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for TuberculosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Sequential
- Model description
- Stepped-Wedge Cluster Randomised Trial design
- Masking
- None (open label)
- Enrolment
- 7,455 participants (actual)
Sponsor and investigators
- Lead sponsor
- Institut de Recherche pour le Developpement
- Sponsor type
- Other government
- Collaborators
- Ministry of Health, Thailand, Tuberculosis and HIV Research Foundation, London School of Hygiene and Tropical Medicine
- Responsible party
- Sponsor
- Investigators
- Christian Lienhardt, Study director, Institut de Recherche pour le Developpement
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05581212
- Sponsor's protocol ID
- IRD-1-001
- Other IDs
- 21SANIN207
- Acronym
- CaPThai
- Status last verified
- Apr 2026
- First submitted
- 17 Jun 2022
- Last updated
- 29 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Tovar Sanchez T, Ngamvithayapong-Yanai J, Grint D, Beneteau S, Luangjna S, Ouedraogo S, Lachenal N, Bonnet M, Fielding K, Kamolwat P, Lienhardt C. Evaluation of a combined tuberculosis case-finding, treatment and prevention strategy in Thailand: protocol for a pragmatic phase IV stepped-wedge cluster-randomised trial, the CaPThai study. Trials. 2026 Feb 16;27(1):225. doi: 10.1186/s13063-026-09532-7.
PubMed 41699679
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Implementation of a New Strategic TB Case-Finding, Treatment and Prevention Public Health Pack in Thailand
- ClinicalTrials.gov ID
- NCT05581212
- Acronym / sponsor ID
- CaPThai / IRD-1-001
- Conditions
- Tuberculosis
- Keywords
- Case-finding, Preventive treatment, Public Health Pack, Household contacts
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 7,455 participants (actual)
- Lead sponsor
- Institut de Recherche pour le DeveloppementOther government
- Collaborators
- Ministry of Health, Thailand, Tuberculosis and HIV Research Foundation, London School of Hygiene and Tropical Medicine
- Study start
- 7 May 2024 (actual)
- Primary completion
- 6 Jan 2026 (actual)
- Study completion
- 7 Jan 2026 (actual)
- First posted
- 14 Oct 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The project aimed to test a strategy for the early detection and prevention of tuberculosis in household contacts of tuberculosis patients in order to reduce the morbidity, mortality and transmission of this disease in Thailand. This strategy will be evaluated in comparison with the current programmatic approach through a pragmatic trial with cluster randomization (cluster randomized controlled trial) which will be conducted over the next 3 years. This project is carried out in collaboration with the Tuberculosis Division of the Ministry of Public Health of Thailand, the TB/HIV Research Foundation in Thailand and the London School of Hygiene and Tropical Medicine in England.
Detailed description
Title: Implementation of a new Strategic TB Case-Finding, Treatment and Prevention Public Health Pack in Thailand (CapThai) Phase: IV, cluster randomized trial
Population:
adults (>= 18 years old) with pulmonary TB and their household contacts. Sites: 20 clusters (provincial hospitals) in Thailand
Duration of the study:
36 months
Subject participation duration:
9 months
Description of the intervention:
Combined active case-finding, treatment and prevention of TB amongst household contacts of TB cases, associated with initiation of SOC treatment in active TB cases and initiation of TB preventive therapy in those contacts without active TB, based on free screening. This intervention will be compared to the standard of care available in the country.
Overall objective:
To evaluate whether a public health intervention package focusing on the households of newly detected TB cases can increase active case-finding and uptake of TB preventive therapy in Thailand.
Specific objectives:
- to compare the initiation and completion of TPT regimens amongst household contacts of infectious TB patients, overall and by gender and age group;
- to evaluate the safety of short TPT regimens amongst HH contacts, overall and by gender and age group;
- to compare the detection of TB and treatment uptake for active TB amongst HH contacts of infectious TB patients, overall and by gender and age group;
- to assess the feasibility of the combined intervention among health care providers and beneficiaries, by gender and age group;
- to assess the acceptability of the combined intervention among health care providers and beneficiaries, by gender and age group;
- to evaluate the epidemiological impact of the combined intervention.
Study design:
The study uses a Stepped-Wedge Cluster Randomised Trial design. Randomisation will take place at the hospital level (cluster: provincial hospitals with >150 new TB cases/year). Twenty clusters will be enrolled and switch from the control to the intervention phase in four sequences every 3 months in a random order until all clusters are exposed to the intervention.
- Intervention Phase: Newly detected bacteriologically confirmed TB patients (≥ 18 years) will be sensitized on the importance of HH contact investigation and TB stigma reduction. They will be asked to enumerate all contacts (name/age/sex/relationship) living in their HH for>1 month at the date of TB diagnostic. Screening invitation cards will be provided for each HH contact (or caregiver for children <13 years old), inviting them to attend the TB clinic at the selected hospital for free screening and evaluation. Transportation fees will be provided. Contacts detected with active TB will receive recommended treatment. In contacts for whom active TB is formally excluded, TPT will be initiated with the new short regimens: (i) children <2 years: isonicotine hydrazine (INH)+rifampicin daily for 3 months; (ii) children 2-12 years: INH+rifapentine weekly for 3 months; (iii) children≥13 and adults: INH+rifapentine daily for 1 month.
- Control phase: current strategy relying on passive case detection and advice provided to TB patients to refer HH contacts to the TB clinic for screening. The index TB patient will be asked to enumerate HH contacts as above and inform them on the need to be screened at the TB clinic.
Endpoints:
Primary endpoint: Proportion of HH contacts with active TB excluded who are initiated on TPT within 4 weeks of the index TB patient diagnosis - overall, by age group (<15, ≥15 years) and gender.
Secondary endpoints:
- Proportion of participants initiated on TPT who completed TPT;
- Proportion of participants in the Intervention phase who were initiated on TPT for whom treatment is discontinued due to intolerance, adverse events, or severe adverse events;
- Proportion of HH contacts with newly diagnosed active TB initiated on curative treatment within 8 weeks of the index TB case diagnosis - overall, by age group (<15, ≥15 years) and gender;
- Proportion of household contacts diagnosed with TB who completed TB treatment in the intervention vs. control phase;
- Proportion of contacts receiving TPT who developed TB over the 9 months follow-up period in the intervention vs. control phase.
Estimated time to complete enrollment:
12-15 months
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Stepped-Wedge Cluster Randomised Trial design
| Arm | Type | Receives |
|---|---|---|
| Standard of Care (Control phase) | No intervention | –In the current standard of care in Thailand, at time of diagnosis and tuberculosis (TB) treatment initiation, TB patients are being advised to tell their household (HH) contacts to consult at the TB clinic for screening and provision of either curative or preventive treatment - according to the screening outcome. |
| Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack (Intervention phase) | Experimental | Other: Tuberculosis Case-Finding, Treatment and Prevention Public Health PackIn the selected provinces, individuals (≥18 years) with newly detected bacteriologically confirmed pulmonary Tuberculosis (index TB case) will be sensitized on the importance of HH contact investigation for detection and prevention of TB and stigma reduction. Index TB cases will be asked to enumerate all persons living in their HH for ≥1 month at the date of TB diagnostic (contact list), and provide their name/age/sex and relationship with the index case. Screening will be offered to each HH contact, using screening invitation cards that will be provided to the index TB case, to be handed over to each HH contact (or caregiver for children <13 years old). Urban and Village Health Volunteers (U/VHV),will visit the HH to enhance awareness of the importance of screening for TB case-finding and prevention and facilitate liaison with the hospital. If active tuberculosis has been formally excluded, they will be eligible to receive the Tuberculosis Preventive Treatment (TPT). |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (7 listed)
- Age ≥18 years
- Newly bacteriologically confirmed TB case (within 1 month of diagnosis)
- Living in the same household for the last 3 months
- Reporting at least one HH contact
- Providing written informed consent for participation in the study
Key exclusion criteria (4 listed)
- Index case who do not live in the catchment area of the study cluster
- Index cases diagnosed with rifampicin resistance, multidrug resistance (MDR) or extensively drug-resistant (XDR-TB)
- Index cases who are incarcerated
- contact currently on TPT or on TB treatment or who finished such treatment in the last 3 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tuberculosis Case-Finding, Treatment and Prevention Public Health PackCombined active case-finding, treatment and prevention of TB amongst HH contacts of TB cases, associated with initiation of standard of care (SOC) treatment in active TB cases and initiation of TB preventive therapy in those contacts without active TB, based on free screening. This intervention will be compared to the standard of care available in the country. | Other | Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack (Intervention phase) |
Primary outcome
Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - overall
Time frame: Month18
Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - overall
Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - by age group (<15, ≥15 years)
Time frame: Month18
Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - by age group (<15, ≥15 years)
Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - by gender
Time frame: Month18
Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - by gender
5 secondary outcomes
Proportion of participants initiated on TPT who completed TPT
Time frame: Month 18
Proportion of participants who initiate TPT for whom treatment is discontinued due to adverse events or intolerance in the Intervention phase
Time frame: Month 18
Proportion of HH contacts with newly diagnosed active TB initiated on curative treatment within 4 weeks of the index TB patient diagnosis - overall
Time frame: Month 18
Proportion of HH contacts with newly diagnosed active TB initiated on curative treatment within 4 weeks of the index TB patient diagnosis - by age group (<15, ≥15 years)
Time frame: Month 18
Proportion of HH contacts with newly diagnosed active TB initiated on curative treatment within 4 weeks of the index TB patient diagnosis - by gender
Time frame: Month 18
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2026.
- Derived from this study: PubMed 41699679Tovar Sanchez T, Ngamvithayapong-Yanai J, Grint D, Beneteau S, Luangjna S, Ouedraogo S, Lachenal N, Bonnet M, Fielding K, Kamolwat P, Lienhardt C. Evaluation of a combined tuberculosis case-finding, treatment and prevention strategy in Thailand: protocol for a pragmatic phase IV stepped-wedge cluster-randomised trial, the CaPThai study. Trials. 2026 Feb 16;27(1):225. doi: 10.1186/s13063-026-09532-7.
Related trials for Tuberculosis
RecruitingPhase 4
Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease
Mycobacterium Avium Complex Pulmonary Disease
RecruitingObservational study
Paradoxical Tuberculosis Reactions in Patients Without HIV Infection
Tuberculosis
Not yet recruitingPhase 2
Re-evaluating the Duration in Children of TB Treatment
Tuberculosis
RecruitingPhase 1/2
A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV
Tuberculosis
Active, not recruitingPhase 3
Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
Tuberculosis, MDR
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Christian Lienhardt study director
Institut de Recherche pour le Developpement
20 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack in people with Tuberculosis, run by Institut de Recherche pour le Developpement at 20 sites in Thailand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 20 sites in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - overall (time frame: Month18). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05581212, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026.